慢性乙型肝炎合并代谢相关脂肪性肝病的研究进展
Research advances in chronic hepatitis B with metabolic dysfunction-associated steatotic liver disease
殷珂 1宋玉芸 1刘峰1
作者信息
- 1. 北京大学人民医院,北京大学肝病研究所,丙型肝炎和肝病免疫治疗北京市重点实验室,非酒精性脂肪性肝病诊断北京市国际科技合作基地,北京 100044
- 折叠
摘要
慢性乙型肝炎(CHB)和脂肪肝是我国常见的慢性肝脏疾病,随着生活方式的改变,CHB合并代谢相关脂肪性肝病的患者逐年增加,两种疾病均存在肝硬化、肝细胞癌(HCC)等不良事件发生的风险.二者共存时肝脏的病理生理学进程与单独的疾病状态可能不同,进而存在HBV的复制,HBsAg的血清学清除及抗病毒治疗受到影响,肝纤维化、HCC等不良事件风险增加的问题,故明确这些问题会对此类患者疾病的监测、治疗及预后有重要意义,本文将对这些问题的最新研究进展进行简要综述.
Abstract
Chronic hepatitis B(CHB)and fatty liver disease are common chronic liver diseases in China.With the changes in lifestyle,the number of patients with CHB and metabolic dysfunction-associated steatotic liver disease(MASLD)is increasing year by year.Both CHB and MASLD may lead to adverse events such as liver cirrhosis and hepatocellular carcinoma(HCC).The pathophysiological course of the liver during the coexistence of the two diseases may be different from the state of each disease alone,and consequently HBV replication may exist,affecting HBsAg seroclearance and antiviral therapy and increasing the risk of adverse events including hepatic fibrosis and HCC.It is clear that these problems will be of great significance to the monitoring,treatment,and prognosis of such patients.Therefore,this article briefly reviews the latest research advances in these problems.
关键词
乙型肝炎,慢性/乙型肝炎病毒/脂肪肝Key words
Hepatitis B,Chronic/Hepatitis B Virus/Fatty Liver引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据